Lenalidomide plus R-GDP (R2-GDP) in Relapsed/Refractory Diffuse Large B-Cell Lymphoma: Final Results of the R2-GDP-GOTEL Trial and Immune Biomarker Subanalysis

PURPOSE: New therapeutic options are needed in relapsed/refractory diffuse large B-cell lymphoma (R/R DLBCL). Lenalidomide-based schedules can reverse rituximab refractoriness in lymphoma. PATIENTS AND METHODS: In the phase II R2-GDP trial, 78 patients unsuitable for autologous stem cell transplant...

Descripción completa

Detalles Bibliográficos
Autores principales: Palazón-Carrión, Natalia, Martín García-Sancho, Alejandro, Nogales-Fernández, Esteban, Jiménez-Cortegana, Carlos, Carnicero-González, Fernando, Ríos-Herranz, Eduardo, de la Cruz-Vicente, Fátima, Rodríguez-García, Guillermo, Fernández-Álvarez, Rubén, Martínez-Banaclocha, Natividad, Gumà-Padrò, Josep, Gómez-Codina, José, Salar-Silvestre, Antonio, Rodríguez-Abreu, Delvys, Gálvez-Carvajal, Laura, Labrador, Jorge, Guirado-Risueño, María, García-Domínguez, Daniel J., Hontecillas-Prieto, Lourdes, Espejo-García, Pablo, Fernández-Román, Isabel, Provencio-Pulla, Mariano, Sánchez-Beato, Margarita, Navarro, Marta, Marylene, Lejeune, Álvaro-Naranjo, Tomás, Casanova-Espinosa, Maria, Sánchez-Margalet, Victor, Rueda-Domínguez, Antonio, de la Cruz-Merino, Luis
Formato: Online Artículo Texto
Lenguaje:English
Publicado: American Association for Cancer Research 2022
Materias:
Research Briefs: Clinical Trial Brief Reports
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9433956/
https://www.ncbi.nlm.nih.gov/pubmed/35727601
http://dx.doi.org/10.1158/1078-0432.CCR-22-0588

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9433956/
https://www.ncbi.nlm.nih.gov/pubmed/35727601
http://dx.doi.org/10.1158/1078-0432.CCR-22-0588

Ejemplares similares